Publications

CHOOSE PROJECT

CHOOSE TARGET

AACR-NCI-EORTC International Conference (ENA) 2024, October 23-25, 2024

Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Discovery of novel MTA-cooperative PRMT5 preclinical candidate as targeted therapeutics for MTAP-deleted cancers

Synthetic Lethality

PRMT5
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors

Synthetic Lethality

WRN
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Exploring Synthetic Lethality and Novel Drug Combinations in Patient-Derived Cells

Synthetic Lethality

Novel Targets
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
European Hematology Association (EHA) Congress, June 13 -16, 2024

RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed/refractory AML and high-risk MDS: preliminary results from two ongoing studies.

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Synergistic potential of RVU120, a first-in-class CDK8/CDK19 inhibitor, with venetoclax in AML: preclinical and initial clinical insights.

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
CDK8/19 Inhibition: A Promising Therapeutic Strategy in Myeloproliferative Neoplasms.

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024

Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers

Synthetic Lethality

PRMT5
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors

Synthetic Lethality

WRN
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
A Comprehensive Platform for Identification of KRAS-specific Synthetic Lethal Targets using Patient-Derived Cells

Synthetic Lethality

Novel Targets
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
MEN1703/SEL24 exhibits promising antitumoral activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

SEL24

MEN1703 (SEL24)
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Combination JAK1/2 and CDK8/19 inhibition demonstrates enhanced efficacy in myeloproliferative neoplasms.

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
American Society of Hematology (ASH) Annual Meeting, December 9 –12, 2023

Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HRMDS: Update from Higher Dose Levels

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Preclinical and Clinical Evidence for Erythroid-Stimulating Activity of RVU120 CDK8/19 Inhibitor in AML and MDS

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Novel Clinically Useful Inhibitor of Mediator Complex, RVU120, Relieves Differentiation Block in MDS/AML

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Targeting CDK8/CDK19 to Disrupt Leukemic Stem Cell-like Population in Acute Myeloid Leukemia: Exploring RVU120 As a Promising Frontline Therapy

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Mediator Kinase/CDK8 Inhibition as a Strategy to Improve FLT3 Inhibitor Activity in Acute Myeloid Leukemia

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023

Synergistic Activity of CDK8/19 Inhibitor RVU120 and MEK Inhibitors in Hormone-Negative Breast Cancer: Implications for Targeted Therapy

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
European Society for Medical Oncology (ESMO) Congress 2023, October 20-24, 2023

Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor, in patients with relapsed/refractory metastatic or advanced solid tumors

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
AACR-NCI-EORTC International Conference (ENA) 2023, October 11-15, 2023

Discovery of Novel MTA-cooperative PRMT5 Inhibitors as Targeted Therapeutics for MTAP-deleted Cancers

PRMT5
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Comprehensive Platform for Unraveling the Molecular Mechanisms and Vulnerabilities of Colorectal Cancer: A Step Forward in Target Discovery
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
MEN1703/SEL24, A Potent PIM Inhibitor, Demonstrates Promising Anti-Tumor Activity in Activated B Cell Like DLBCL, Mantle Cell Lymphoma and Marginal Zone Lymphoma Cells

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Congress of the Polish Society of Hematology and Transfusion Medicine, September 14-16, 2023

Safety and Efficacy Update from CLI120–001: a Phase 1b Dose Escalation Study in Relapse-Refractory Acute Myeloid Leukemia and High-Risk Myelodysplasia

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
RVU120 CDK8/19 Inhibitor Promotes Erythroid Differentiation in AML and HR-MDS Patients

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
European Hematology Association (EHA) Hybrid Congress, June 8-11, 2023

Safety and efficacy update from CLI120-001: a Phase 1b dose-escalation study in relapse/refractory AML and HR-MDS

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Combination JAK1/2 and CDK8/19 inhibition demonstrates enhanced efficacy in myeloproliferative neoplasms

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
American Association for Cancer Research (AACR) Annual Meeting, April 14-19, 2023

Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers

PRMT5
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
American Society of Hematology (ASH) Annual Meeting, December 10 –13, 2022

CDK8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Multiomics Analysis Confirms Effective Target Engagement for RVU120 – a First-in-class CDK8/19 Kinase Inhibitor in AML and MR-MDS Patients and Reveals the Mechanism of Action

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
PIM Inhibition by SEL24 (MEN1703) Combines Synergistically with gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Super-enhancer-driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-specific Oncogenic and Microenvironmental Circuits and Can Be Efficiently Targeted by the Pan-PIM Inhibitor MEN1703

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
PIM Kinases Regulate Super-Enhancer-Dependent Gene Expression In Diffuse Large B-Cell Lymphoma

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
MEN1703-mediated PIM kinases inhibition impairs protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
EORTC-NCI-AACR Symposium (ENA), October 26-28, 2022

Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
RVU120, a small molecule inhibitor of CDK8/19 kinases, enhances rituximab-driven NK cells-mediated cytotoxicity both in vitro and in vivo

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP deleted cancers

PRMT5
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
European Hematology Association (EHA) Hybrid Congress, June 9-17, 2022

CLI120-001 Phase1b Dose Escalation Study of RVU120 in Patients with AML or High-Risk MDS Safety and Efficacy Data Update

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Preclinical and Clinical Signs of RVU120 efficacy, a Specific CDK8/19 Inhibitor in DNMT3A and NPM1 Mutation Positive AML and HR-MDS

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Phase 1/2 Study of SEL24/MEN1703, a First-In-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients with IDH1/2-Mutated Acute Myeloid Leukemia: the DIAMOND-01 Trial

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022

Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: the DIAMOND-01 trial

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Phase I/II trial of RVU120 (SEL120), a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022

"RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo"

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Discovery of novel MTA-cooperative PRMT5 inhibitors as a targeted therapeutic for MTAP deleted cancers"

PRMT5
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"RVU120 SOL-021: An open-label, single agent, Phase I/II trial of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors"

RVU120

CDK8/CDK19
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
63rd American Society of Hematology (ASH) Annual Meeting & Exposition, December 11 – 14, 2021

"CLI120-001 Phase Ib Study of RVU120 (SEL120) in Patients with AML and High-Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"RVU120 – a CDK8/19 Inhibitor for the Treatment of AML and HR-MDS Can Induce Erythroid Differentiation"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Inhibition of Cyclin Dependent Kinase 8 (CDK8): A Novel Approach to Target the Leukemia Initiating Cells (LICs) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"SEL24(MEN1703) Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial"

RVU120

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
44th Annual San Antonio Breast Cancer Symposium (SABCS), December 7-10, 2021

"Selective CDK8/CDK19 inhibitor RVU120 demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting, November 11-14, 2021

"Novel, orally administered HPK1 inhibitors demonstrate anti-tumor efficacy and enhanced immune response"

HPK1
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Characterization of RVU-27065 a novel small-molecule STING agonist suitable for systemic administration"

STING
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Discovery of 5-{2-[5-Chloro-2-(5-ethoxyquinoline-8-sulfonamido)phenyl]ethynyl}-4-methoxypyridine-2-carboxylic Acid, a Highly Selective in Vivo Useable Chemical Probe to Dissect MCT4 Biology

Heinrich T, Sala-Hojman A, Ferretti R, Petersson C, Minguzzi S, Gondela A, Ramaswamy S, Bartosik A et al. Discovery of 5-{2-[5-Chloro-2-(5-ethoxyquinoline-8-sulfonamido)phenyl]ethynyl}-4-methoxypyridine-2-carboxylic Acid, a Highly Selective in Vivo Useable Chemical Probe to Dissect MCT4 Biology. Journal of Medicinal Chemistry, August 2021
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Virtual 26th Annual European Hematology Association (EHA) Congress, June 9-17, 2021

"RVU120/SEL120 CDK8/19 inhibitor - a drug candidate for the treatment of MDS can induce erythroid differentiation in transformed CD34+ hematopoietic progenitor cells"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"CLI120-001 Phase 1b Study of SEL120/RVU120 in patients with AML or High Risk MDS: Preliminary clinical and PK results from initial dose escalation cohorts"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
“Results from DIAMOND-01 (CLI24-001) TRIAL: First in Human Study of SEL24/MEN1703, a Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia”

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
AACR Virtual Annual Meeting 2021, April 10-15 and May 17-21, 2021

"RVU120 (SEL120), a CDK8/CDK19 inhibitor, possesses strong multilineage differentiation potential in leukemic cells"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Development and characterization of small molecule HPK1 inhibitors"

HPK1
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"New generation of STING agonists: development and characterization of a novel series of systemic immunomodulators with improved potency"

STING
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020

"SEL24/MEN1703 provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamic (PD) Assay in the Dose Escalation Part of First-in-Human DIAMOND-01 Trial"

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"PIM Kinase Inhibition Decreases the Proangiogenic Properties of Multiple Myeloma Cells and Affects the Metabolic State of the Vascular Endothelium"

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting, November 11-14, 2020

"Development of improved small molecule STING agonists suitable for systemic administration"

STING
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
AACR Virtual Annual Meeting II, June 22-24, 2020

"Synergistic effect of CDK8 and BCL-2 inhibition in AML through regulation of MCL-1 and BIM balance"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"In vivo and in vitro characterization of RVU330 best-in-class dual A2A/A2B adenosine receptor antagonist"

A2A/A2B
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Development of selective small molecule STING agonists suitable for systemic administration"

STING
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Development and characterization of small molecule HPK1 inhibitors"

HPK1
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors"

SMARCA
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Virtual 25th Annual European Hematology Association (EHA) Congress, June 11-21, 2020

“A First-in-human study of SEL120, a novel oral selective CDK8/19 inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome”

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Results of the dose escalation part of DIAMOND trial (CLI24-001): first in human study of SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor, in Patients with Acute Myeloid Leukemia"

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes

Podkalicka, P.; Mucha, O.; Kruczek, S.; Biela, A.; Andrysiak, K.; Stępniewski, J.; Mikulski, M.; Gałęzowski, M.; Sitarz, K.; Brzózka, K.; Józkowicz, A.; Dulak, J.; Łoboda, A. Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes. Biomolecules 2020, 10, 143.
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
61st American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL, USA

"SEL120 – a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019), November 6–10, National Harbor, MD, USA

"Novel dual A2A /A2B adenosine receptor antagonists for cancer immunotherapy in vitro characterization"

A2A/A2B
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Development and characterization of next generation small molecule STING agonists"

STING
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
CICON 2019 – Translating Science into Survival – September 25-28, 2019, Paris, France

“Characterization of novel potent dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy”

A2A/A2B
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
24th Congress of EHA, June 13-16, 2019 Amsterdam, Netherlands

"CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia"

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
ASCO Annual Meeting 2019, May 31-June 4, Chicago, IL, USA

"CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia"

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
AACR Annual Meeting 2019, March 29- April 3, 2019, Atlanta, GA, USA

"SEL120, a Potent and Specific Inhibitor of CDK8 Induces Complete Remission in Human Patient Derived Xenograft Models of Acute Myeloid Leukemia (AML)"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Novel dual A2A /A2B adenosine receptor antagonists for cancer immunotherapy in vitro and in vivo characterization"

A2A/A2B
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Discovery and characterization of next-generation small molecule direct STING agonists"

STING
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
American Society of Hematology (ASH) Annual Meeting, 1-4 December 2018, San Diego, CA, USA

"CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human AML Models"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, 13-16 November 2018, Dublin, Ireland

“SEL120−34A, a potent and specific inhibitor of CDK8, as a potential treatment of acute myeloid and lymphoblastic leukemias”

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC), 7-11 November 2018, Washington, DC, USA

"Novel class of small molecule direct STING agonists as a potential cancer immunotherapy"

STING
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
“Characterization of novel dual A2A/B adenosine receptor antagonists for cancer immunotherapy”

A2A/A2B
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Mechanisms to Therapies: Innovations in Cancer Metabolism, 9-11 October 2018, Bilbao, Spain

"Discovery of novel SHMT1/2 small molecule inhibitors for cancer treatment"

SHMT
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice, 3-5 October 2018, Dubrovnik, Croatia

“CDK8 inhibitor SEL120 targets AML by regulation of transcriptional programs involved in the maintenance of leukemia stem cells”

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
Annual Immuno-Oncology Summit, 27-31 August 2018, Boston, MA, USA

"Discovery of novel small molecule STING agonists as a new cancer immunotherapy"

STING
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
“Characterization of novel dual A2A/B adenosine receptor antagonists for cancer immunotherapy”

A2A/A2B
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
AACR Annual Meeting 2018, 14-18 April 2018, Chicago, IL, USA

"Characterization of novel dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy"

A2A/A2B
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"CDK8 inhibitor SEL120-34A targets CD34 positive AML cells by regulation of transcriptional programs involved in the maintenance of leukemia stem cells"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Discovery of novel SHMT small molecule inhibitors for cancer treatment"

SHMT
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
AACR Annual Meeting 2017, 1 - 5 April 2017, Washington, DC, USA

"Development of small molecule selective inhibitors of GCN2 as an immunotherapy aimed at preventing immune escape of tumor cells"

GCN2
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Differential activity on lung adenocarcinoma cells with loss-of-function mutations of SWI/SNF protein SMARCA4"

SMARCA
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Small molecule inhibitors of SHMT1/2 validate serine metabolism as a target in the treatment of c-Myc positive solid tumors"

SHMT
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Inhibition of CDK8 kinase with SEL120-34A allows for a personalized approach in AML"

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
"Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies"

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
AACR Annual Meeting 2015, 18 – 22 April 2015 in Philadelphia, PA, USA:

“First-in-class dual PIM/FLT3 inhibitor SEL24-B489 for the treatment of hematological malignancies”

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
“Selective CDK8 inhibitor SEL120-34A alters expression of interferon-related DNA damage resistance signature genes in colorectal cancer”

RVU120

CDK8
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
AACR Annual Meeting 2014, 5-9 April 2014, San Diego, USA:

“Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies”

SEL24

PIM/FLT3
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link
“Repression of tumor survival pathways by novel, selective inhibitors of MNK1 and MNK2 kinases”

MNK
To download chosen material please fill in form below:
NAME & SURNAME

COMPANY NAME

ADRESS E-MAIL

PHONE NUMBER

The controller of your personal data is Ryvu Therapeutics S.A., which manages the website www.ryvu.com.pl. (hereinafter: “Website”). We process your personal data in order to send you a poster about our scientific projects and to measure the interest in our research.
You have the right to access your data, the right to request their rectification or erasure, the right to object and other rights described in detail in our Privacy Policy. Detailed information on the processing of your personal data: Link

Investors & Media

AACR-NCI-EORTC International Conference (ENA) 2024, October 23-25, 2024

European Hematology Association (EHA) Congress, June 13 -16, 2024

American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024

American Society of Hematology (ASH) Annual Meeting, December 9 –12, 2023

San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023

European Society for Medical Oncology (ESMO) Congress 2023, October 20-24, 2023

AACR-NCI-EORTC International Conference (ENA) 2023, October 11-15, 2023

Congress of the Polish Society of Hematology and Transfusion Medicine, September 14-16, 2023

European Hematology Association (EHA) Hybrid Congress, June 8-11, 2023

American Association for Cancer Research (AACR) Annual Meeting, April 14-19, 2023

American Society of Hematology (ASH) Annual Meeting, December 10 –13, 2022

EORTC-NCI-AACR Symposium (ENA), October 26-28, 2022

European Hematology Association (EHA) Hybrid Congress, June 9-17, 2022

American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022

American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022

63rd American Society of Hematology (ASH) Annual Meeting & Exposition, December 11 – 14, 2021

44th Annual San Antonio Breast Cancer Symposium (SABCS), December 7-10, 2021

Society for Immunotherapy of Cancer’s (SITC) 36th Anniversary Annual Meeting, November 11-14, 2021

Discovery of 5-{2-[5-Chloro-2-(5-ethoxyquinoline-8-sulfonamido)phenyl]ethynyl}-4-methoxypyridine-2-carboxylic Acid, a Highly Selective in Vivo Useable Chemical Probe to Dissect MCT4 Biology

Virtual 26th Annual European Hematology Association (EHA) Congress, June 9-17, 2021

AACR Virtual Annual Meeting 2021, April 10-15 and May 17-21, 2021

62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020

Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting, November 11-14, 2020

AACR Virtual Annual Meeting II, June 22-24, 2020

Virtual 25th Annual European Hematology Association (EHA) Congress, June 11-21, 2020

Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes

61st American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, Orlando, FL, USA

Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019), November 6–10, National Harbor, MD, USA

CICON 2019 – Translating Science into Survival – September 25-28, 2019, Paris, France

24th Congress of EHA, June 13-16, 2019 Amsterdam, Netherlands

ASCO Annual Meeting 2019, May 31-June 4, Chicago, IL, USA

AACR Annual Meeting 2019, March 29- April 3, 2019, Atlanta, GA, USA

American Society of Hematology (ASH) Annual Meeting, 1-4 December 2018, San Diego, CA, USA

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, 13-16 November 2018, Dublin, Ireland

Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC), 7-11 November 2018, Washington, DC, USA

Mechanisms to Therapies: Innovations in Cancer Metabolism, 9-11 October 2018, Bilbao, Spain

Leukemia and Lymphoma – Europe and the USA Linking Knowledge and Practice, 3-5 October 2018, Dubrovnik, Croatia

Annual Immuno-Oncology Summit, 27-31 August 2018, Boston, MA, USA

AACR Annual Meeting 2018, 14-18 April 2018, Chicago, IL, USA

AACR Annual Meeting 2017, 1 - 5 April 2017, Washington, DC, USA

AACR Annual Meeting 2015, 18 – 22 April 2015 in Philadelphia, PA, USA:

AACR Annual Meeting 2014, 5-9 April 2014, San Diego, USA:

Subscribe to receive news updates from Ryvu Therapeutics